| Title |
Pseudovirions as Vehicles for the Delivery of siRNA
|
|---|---|
| Published in |
Pharmaceutical Research, December 2009
|
| DOI | 10.1007/s11095-009-0012-2 |
| Pubmed ID | |
| Authors |
Paul E. Lund, Ryan C. Hunt, Michael M. Gottesman, Chava Kimchi-Sarfaty |
| Abstract |
Over the last two decades, small interfering RNA (siRNA)-mediated gene silencing has quickly become one of the most powerful techniques used to study gene function in vitro and a promising area for new therapeutics. Delivery remains a significant impediment to realizing the therapeutic potential of siRNA, a problem that is also tied to immunogenicity and toxicity. Numerous delivery vehicles have been developed, including some that can be categorized as pseudovirions: these are vectors that are directly derived from viruses but whose viral coding sequences have been eliminated, preventing their classification as viral vectors. Characteristics of the pseudovirions discussed in this review, namely phagemids, HSV amplicons, SV40 in vitro-packaged vectors, influenza virosomes, and HVJ-Envelope vectors, make them attractive for the delivery of siRNA-based therapeutics. Pseudovirions were shown to deliver siRNA effector molecules and bring about RNA interference (RNAi) in various cell types in vitro, and in vivo using immune-deficient and immune-competent mouse models. Levels of silencing were not always determined directly, but the duration of siRNA-induced knockdown lasted at least 3 days. We present examples of the use of pseudovirions for the delivery of synthetic siRNA as well as the delivery and expression of DNA-directed siRNA. |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 49 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 24% |
| Student > Bachelor | 11 | 22% |
| Student > Ph. D. Student | 10 | 20% |
| Student > Master | 5 | 10% |
| Student > Doctoral Student | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 11 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 18 | 35% |
| Biochemistry, Genetics and Molecular Biology | 13 | 25% |
| Immunology and Microbiology | 3 | 6% |
| Medicine and Dentistry | 3 | 6% |
| Unspecified | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 12 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2024.
All research outputs
#5,595,291
of 23,524,722 outputs
Outputs from Pharmaceutical Research
#504
of 2,893 outputs
Outputs of similar age
#27,590
of 168,523 outputs
Outputs of similar age from Pharmaceutical Research
#1
of 16 outputs
Altmetric has tracked 23,524,722 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,893 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,523 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.